Prihlásiť sa Zaregistrujte sa zadarmo

RSI spoločnosti Cue Biopharma Inc

Aká je hodnota metriky RSI spoločnosti Cue Biopharma Inc?

Hodnota metriky RSI spoločnosti Cue Biopharma Inc je 36.11

Aká je definícia metriky RSI?

Index relatívnej sily (Relative strength index - RSI 14) je technický ukazovateľ, ktorý sa radí medzi momentum indikátory a meria rýchlosť a zmenu ceny. Jeho hodnota sa pohybuje medzi 0 a 100 a používa sa na charakterizovanie prekupovaného a prepredaného stavu.

It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.

Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.

RSI spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Cue Biopharma Inc

Čomu sa venuje spoločnosť Cue Biopharma Inc?

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Firmy s metrikou rsi podobnou spoločnosti Cue Biopharma Inc